{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:08:08Z","timestamp":1765004888145,"version":"3.41.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,25]],"date-time":"2018-04-25T00:00:00Z","timestamp":1524614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.ejphar.2018.04.014","type":"journal-article","created":{"date-parts":[[2018,4,22]],"date-time":"2018-04-22T21:44:34Z","timestamp":1524433474000},"page":"26-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol"],"prefix":"10.1016","volume":"830","author":[{"given":"Takashi","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoko","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroko","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.04.014_bib1","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.jphs.2015.01.007","article-title":"Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range","volume":"127","author":"Baba","year":"2015","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejphar.2018.04.014_bib2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0306-4522(91)90108-Z","article-title":"Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study","volume":"45","author":"Bernard","year":"1991","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejphar.2018.04.014_bib3","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1126\/science.847477","article-title":"Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain","volume":"196","author":"Burt","year":"1977","journal-title":"Science"},{"key":"10.1016\/j.ejphar.2018.04.014_bib4","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1016\/j.euroneuro.2015.10.002","article-title":"5-HT2 receptors modulate the expression of antipsychotic-induced dopamine supersensitivity","volume":"25","author":"Charron","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0920-9964(91)90050-2","article-title":"Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment","volume":"5","author":"Chouinard","year":"1991","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib6","first-page":"891","article-title":"Supersensitivity psychosis and tardive dyskinesia: a survey I schizophrenic outpatients","volume":"22","author":"Chouinard","year":"1986","journal-title":"Psychopharmacol. Bull."},{"key":"10.1016\/j.ejphar.2018.04.014_bib7","doi-asserted-by":"crossref","first-page":"21S","DOI":"10.1097\/00004714-198808001-00005","article-title":"A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases","volume":"8","author":"Chouinard","year":"1988","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1176\/ajp.137.1.16","article-title":"Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics","volume":"137","author":"Chouinard","year":"1980","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.04.014_bib9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2165\/11202620-000000000-00000","article-title":"Blonanserin: a review of its use in the management of schizophrenia","volume":"24","author":"Deeks","year":"2010","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2018.04.014_bib10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/S0028-3908(97)00163-9","article-title":"Antipsychotic regulation of dopamine D1, D2 and D3 receptor mRNA","volume":"36","author":"D'Souza","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2018.04.014_bib11","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0014-5793(94)80385-4","article-title":"The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain","volume":"339","author":"Fishbum","year":"1994","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejphar.2018.04.014_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.bbr.2013.09.050","article-title":"Time-dependence of risperidone and asenapine sensitization and associated D2 receptor mechanism","volume":"257","author":"Gao","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/0024-3205(91)90367-K","article-title":"Haloperidol treatment increases D2 dopamine receptor protein independently of RNA levels in mice","volume":"48","author":"Goss","year":"1991","journal-title":"Life Sci."},{"key":"10.1016\/j.ejphar.2018.04.014_bib14","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejphar.2007.06.035","article-title":"The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats","volume":"572","author":"Gyerty\u00e1n","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib15","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0197-0186(96)00093-9","article-title":"Effects of chronic neuroleptic treatments on dopamine D1 and D2 receptors: homogenate binding and autoradiographic studies","volume":"30","author":"Huang","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.ejphar.2018.04.014_bib16","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0014-2999(96)00920-X","article-title":"Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D 2 receptor following repeated treatment in the rat striatum","volume":"321","author":"Inoue","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(96)00948-X","article-title":"Effects of serotonergic agents on the up-regulation of dopamine D2 receptors induced by haloperidol in rat striatum","volume":"321","author":"Ishikane","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/JCP.0b013e31828ea95c","article-title":"Optimal extent of dopamine D2 receptor occupancy by antipsychotics for treatment of dopamine supersensitivity psychosis and late-onset psychosis","volume":"33","author":"Iyo","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib19","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jpsychires.2012.10.011","article-title":"Blonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trials","volume":"47","author":"Kishi","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib20","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0304-3940(94)90248-8","article-title":"A new animal model of dopamine supersensitivity using s.c. implantation of haloperidol releasing polymers","volume":"170","author":"K\u00f6hler","year":"1994","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2018.04.014_bib21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.bbr.2016.02.031","article-title":"The atypical antipsychotic blonanserin reverses (+)-PD-128907- and ketamine-induced deficit in executive function in common marmosets","volume":"305","author":"Kotani","year":"2016","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S0028-3908(03)00314-9","article-title":"Elevated neuronal nitric oxide synthase expression in chronic haloperidol-treated rats","volume":"45","author":"Lau","year":"2003","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejphar.2018.04.014_bib23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1073\/pnas.92.5.1719","article-title":"A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons","volume":"92","author":"L\u00e9vesque","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejphar.2018.04.014_bib24","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpsychires.2015.07.015","article-title":"Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: a double-blind, parallel-group multicenter randomized trial","volume":"69","author":"Li","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"193","author":"Lowry","year":"1951","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.04.014_bib26","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archpsyc.1982.04290090001001","article-title":"Increased brain dopamine and dopamine receptors in schizophrenia","volume":"39","author":"Mackay","year":"1982","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.04.014_bib27","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1016\/S0014-2999(97)00049-6","article-title":"The dopamine D3 receptor antagonist, (+)-S 14297, blocks the cataleptic properties of haloperidol in rats","volume":"321","author":"Millan","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib28","first-page":"845","article-title":"Dopamine-serotonin antagonist: receptor binding profile of a novel antipsychotic blonanserin. Jpn","volume":"11","author":"Murasaki","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib29","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/00001756-200302100-00023","article-title":"Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice","volume":"14","author":"Nagai","year":"2003","journal-title":"Neuroreport"},{"key":"10.1016\/j.ejphar.2018.04.014_bib30","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0022-3565(25)38164-4","article-title":"Comparative study of 2-(4-ethyl-1-piperazinyl)-4-(fluorophenyl)-5,6,7,8,9, 10-hexahydrocycloocta[b]pyridine (AD-5423) and haloperidol for their pharmacological activities related to antipsychotic efficacy and\/or adverse side-effects","volume":"265","author":"Noda","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.04.014_bib31","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1177\/0269881115593903","article-title":"G protein-coupled receptor kinase 6\/\u03b2-arrestin 2 system in a rat model of dopamine supersensitivity psychosis","volume":"29","author":"Oda","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0022-3565(25)10246-2","article-title":"Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties","volume":"264","author":"Oka","year":"1993","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.04.014_bib33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0006-8993(00)02247-2","article-title":"The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine","volume":"867","author":"Richtand","year":"2000","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.04.014_bib34","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/sj.npp.1301305","article-title":"Dopamine and serotonin receptor binding and antipsychotic efficacy","volume":"32","author":"Richtand","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.ejphar.2018.04.014_bib35","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/0922-4106(91)90092-V","article-title":"Up-regulation of dopamine D2 receptor mRNA in rat striatum by chronic neuroleptic treatment","volume":"207","author":"Rogue","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.04.014_bib36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biopsych.2008.01.010","article-title":"Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery","volume":"64","author":"Samaha","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.04.014_bib37","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1523\/JNEUROSCI.5416-06.2007","article-title":"\"Breakthrough\" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time","volume":"27","author":"Samaha","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2018.04.014_bib38","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.ejphar.2018.04.014_bib39","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pnpbp.2013.10.003","article-title":"Is schizophrenia a dopamine supersensitivity psychotic reaction?","volume":"48","author":"Seeman","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.04.014_bib40","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.pnpbp.2013.12.013","article-title":"Role of cerebellar dopamine D(3) receptors in modulating exploratory locomotion and cataleptogenicity in rats","volume":"50","author":"Shimizu","year":"2014","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2018.04.014_bib41","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s002130000532","article-title":"Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study","volume":"152","author":"Silvestri","year":"2000","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.ejphar.2018.04.014_bib42","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0149-7634(00)00014-2","article-title":"The adolescent brain and age-related behavioral manifestations","volume":"24","author":"Spear","year":"2000","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.ejphar.2018.04.014_bib43","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/BF02896840","article-title":"Effect of haloperidol on expression of dopamine D2 receptor mRNAs in rat brain","volume":"2","author":"Srivastava","year":"1990","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.ejphar.2018.04.014_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1254\/jphs.12096SC","article-title":"Pramipexole upregulates dopamine receptor D\u2082 and D\u2083 expression in rat striatum","volume":"120","author":"Tokunaga","year":"2012","journal-title":"J. Pharmacol. Sci."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918302267?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918302267?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T21:05:22Z","timestamp":1751576722000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918302267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":44,"alternative-id":["S0014299918302267"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.04.014","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lack of dopamine supersensitivity in rats after chronic administration of blonanserin: Comparison with haloperidol","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}